What is ReShape Lifesciences' stock price target for 2024?

0 Wall Street analysts have issued 1-year target prices for ReShape Lifesciences' shares. Their RSLS share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 4,763.5% from the stock's current price. View analysts price targets for RSLS or view top-rated stocks among Wall Street analysts .

How have RSLS shares performed in 2024?

ReShape Lifesciences' stock was trading at $0.2497 at the beginning of the year. Since then, RSLS shares have decreased by 34.1% and is now trading at $0.1645. View the best growth stocks for 2024 here .

Are investors shorting ReShape Lifesciences?

ReShape Lifesciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 729,300 shares, an increase of 70.1% from the March 15th total of 428,700 shares. Based on an average trading volume of 807,600 shares, the short-interest ratio is presently 0.9 days. Currently, 3.5% of the shares of the stock are short sold. View ReShape Lifesciences' Short Interest .

When is ReShape Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RSLS earnings forecast .

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (NASDAQ:RSLS) released its quarterly earnings data on Thursday, August, 13th. The medical device company reported ($8.67) EPS for the quarter, beating the consensus estimate of ($218,400.00) by $218,391.33. The medical device company had revenue of $1.70 million for the quarter. ReShape Lifesciences had a negative trailing twelve-month return on equity of 187.89% and a negative net margin of 131.22%.

When did ReShape Lifesciences' stock split?

ReShape Lifesciences shares reverse split on Thursday, December 22nd 2022. The 1-50 reverse split was announced on Thursday, December 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of ReShape Lifesciences?

Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RSLS

ReShape Lifesciences (RSLS) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free RSLS Stock Alerts

$0.16

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.16
▼
$0.17
50-Day Range: $0.15
▼
$0.20
52-Week Range: $0.14
▼
$4.10

Volume: 169,774 shs
Average Volume: 794,166 shs
Market Capitalization: $2.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get ReShape Lifesciences alerts:

ReShape Lifesciences MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 4,763.5% Upside
$8.00 Price Target
Short Interest: Healthy
3.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.02
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.43 out of 5 stars

2.0

Analyst's Opinion

Amount of Analyst Coverage
ReShape Lifesciences has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.50% of the float of ReShape Lifesciences has been sold short.
Short Interest Ratio / Days to Cover
ReShape Lifesciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ReShape Lifesciences has recently increased by 70.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ReShape Lifesciences does not currently pay a dividend.
Dividend Growth
ReShape Lifesciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RSLS.

1.1

News and Social Media Coverage

News Sentiment
ReShape Lifesciences has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for ReShape Lifesciences this week, compared to 1 article on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ReShape Lifesciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.10% of the stock of ReShape Lifesciences is held by insiders.
Percentage Held by Institutions
Only 22.06% of the stock of ReShape Lifesciences is held by institutions.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
ReShape Lifesciences has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

To get all the details of this controversial tech – click here now.

About ReShape Lifesciences Stock (NASDAQ:RSLS)

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

RSLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RSLS Stock News Headlines

April 15, 2024 | americanbankingnews.com

Spectral Medical (OTCMKTS:EDTXF) & ReShape Lifesciences (NASDAQ:RSLS) Head to Head Analysis

April 14, 2024 | americanbankingnews.com

ReShape Lifesciences (RSLS) Scheduled to Post Earnings on Monday

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

April 7, 2024 | seekingalpha.com

RSLS ReShape Lifesciences Inc.

April 3, 2024 | msn.com

Will GLP-1 medications replace weight loss surgery?

April 3, 2024 | finance.yahoo.com

ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

April 2, 2024 | finance.yahoo.com

Q4 2023 ReShape Lifesciences Inc Earnings Call

April 1, 2024 | globenewswire.com

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

March 29, 2024 | benzinga.com

Latest News for Reshape Lifesciences Stock (NASDAQ:RSLS)

March 28, 2024 | finanznachrichten.de

ReShape Lifesciences Inc: ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

March 28, 2024 | globenewswire.com

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

March 4, 2024 | msn.com

ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan

March 4, 2024 | globenewswire.com

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

February 29, 2024 | investing.com

ReShape Lifesciences Inc (RSLS)

February 29, 2024 | edition.cnn.com

ReShape Lifesciences, Inc.

February 24, 2024 | thestreet.com

ReShape Lifesciences Inc.

February 22, 2024 | benzinga.com

Reshape Lifesciences Stock (NASDAQ:RSLS) Insider Trades

February 22, 2024 | finance.yahoo.com

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

February 22, 2024 | finance.yahoo.com

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

February 22, 2024 | globenewswire.com

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

January 24, 2024 | finance.yahoo.com

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

December 20, 2023 | marketwatch.com

ReShape Lifesciences Shares Rise 5.6% on Potential Strategic Merger and Acquisition Partnership Alternatives

December 13, 2023 | msn.com

Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

December 13, 2023 | msn.com

Why ReShape Lifesciences Stock Is Ripping Higher

December 13, 2023 | investorplace.com

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

December 13, 2023 | finanznachrichten.de

ReShape Lifesciences Inc: ReShape Lifesciences Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band 2.0 FLEX

See More Headlines

Receive RSLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/13/2020
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:RSLS
CUSIP: 29365M20
CIK: 1371217
Web: www.reshapelifesciences.com
Phone: (949) 429-6680
Fax: N/A
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +4,763.5%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,390,000.00
Net Margins: -131.22%
Pretax Margin: -130.62%
Return on Equity: -187.89%
Return on Assets: -97.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.73
Quick Ratio: 1.74

Sales & Book Value

Annual Sales: $8.68 million
Price / Sales: 0.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.51 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 13,140,000
Free Float: 13,122,000
Market Cap: $2.16 million
Optionable: Not Optionable
Beta: 0.22

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Dan W. Gladney (Age 71)
Executive Chair
Comp: $95.26k
Mr. Paul F. Hickey (Age 59)
CEO, President & Director
Comp: $158.08k
Mr. Thomas Stankovich (Age 63)
Chief Financial Officer
Comp: $555.84k
Dr. Mark B. Knudson Ph.D. (Age 75)
Co-Founder and Special Advisor to the CEO
Comp: $33k
Dr. Katherine S. Tweden Ph.D. (Age 63)
Co-Founder
Comp: $338.41k
Mr. Al Diaz
Vice President of Operations and R&D
Dr. Dov Gal D.V.M.
M.B.A., VP of Regulatory Clinical Quality & Compliance Officer
Jody B. Dahlman
Director of Communications
Mr. Naqeeb A. Ansari (Age 63)
Senior Vice President of Global Commercial Operations
Comp: $327.46k

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

RSLS Stock Analysis - Frequently Asked Questions

What is ReShape Lifesciences' stock price target for 2024?: 0 Wall Street analysts have issued 1-year target prices for ReShape Lifesciences' shares. Their RSLS share price targets range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 4,763.5% from the stock's current price.
View analysts price targets for RSLS or view top-rated stocks among Wall Street analysts.
How have RSLS shares performed in 2024?: ReShape Lifesciences' stock was trading at $0.2497 at the beginning of the year. Since then, RSLS shares have decreased by 34.1% and is now trading at $0.1645.
View the best growth stocks for 2024 here.
Are investors shorting ReShape Lifesciences?: ReShape Lifesciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 729,300 shares, an increase of 70.1% from the March 15th total of 428,700 shares. Based on an average trading volume of 807,600 shares, the short-interest ratio is presently 0.9 days. Currently, 3.5% of the shares of the stock are short sold.
View ReShape Lifesciences' Short Interest.
When is ReShape Lifesciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RSLS earnings forecast.

How were ReShape Lifesciences' earnings last quarter?: ReShape Lifesciences Inc. (NASDAQ:RSLS) released its quarterly earnings data on Thursday, August, 13th. The medical device company reported ($8.67) EPS for the quarter, beating the consensus estimate of ($218,400.00) by $218,391.33. The medical device company had revenue of $1.70 million for the quarter. ReShape Lifesciences had a negative trailing twelve-month return on equity of 187.89% and a negative net margin of 131.22%.
When did ReShape Lifesciences' stock split?: ReShape Lifesciences shares reverse split on Thursday, December 22nd 2022. The 1-50 reverse split was announced on Thursday, December 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
How do I buy shares of ReShape Lifesciences?: Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RSLS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ReShape Lifesciences (RSLS) Stock Price, News & Analysis

ReShape Lifesciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Price to Book Value per Share Ratio

About ReShape Lifesciences Stock (NASDAQ:RSLS)

RSLS Stock Price History

RSLS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

RSLS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™